7Baggers
 Inmune Bio Submits Manuscript on Alzheimer’s Trial  TipRanks Tue, 30 Sep 2025 20:36:17 GMT
 INmune Bio submits manuscript on Phase 2 Alzheimer’s trial results  Investing.com Mon, 29 Sep 2025 12:30:08 GMT
 inmune bio, inc. (nasdaq:inmb) short interest update  MarketBeat Sun, 21 Sep 2025 00:45:00 GMT
 INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update  MarketBeat Sat, 20 Sep 2025 07:00:00 GMT
 inmune bio, inc. (nasdaq:inmb) short interest down 29.8% in august  MarketBeat Sat, 20 Sep 2025 02:58:27 GMT
 inmune bio, inc. (nasdaq:inmb) sees large drop in short interest  MarketBeat Wed, 17 Sep 2025 12:43:35 GMT
 inmune bio, inc. (nasdaq:inmb) short interest down 29.8% in august  MarketBeat Wed, 17 Sep 2025 12:43:35 GMT
 published on: 2025-09-16 12:20:17  خودرو بانک Tue, 16 Sep 2025 08:54:28 GMT
 brokerages set inmune bio, inc. (nasdaq:inmb) pt at $18.40  MarketBeat Tue, 16 Sep 2025 08:42:02 GMT
 inmune bio reverses early gains after stock offering  MSN Sun, 31 Aug 2025 11:30:15 GMT
 inmune bio reverses early gains after stock offering  MSN Sat, 30 Aug 2025 19:09:59 GMT

INmune Bio, Inc
(NASDAQ:INMB) 

INMB stock logo

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid t...

Full Time Employees: 4
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends